| Drug Name |
Cisplatin
|
||
| Synonyms |
Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)
|
||
| Drug Type |
Small molecular drug
|
||
| Indications |
Osteosarcoma [ICD-11: 2B51]
|
Phase 2
|
|
|
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
|
Approved
|
||
| Company |
Bristol-Myers Squibb
|
||
| Summary |
Cisplatin is a platinum based chemotherapy agent used to treat various sarcomas, carcinomas, lymphomas, and germ cell tumors.
|
||
| Target |
Human Deoxyribonucleic acid (hDNA)
Mechanism of Action: Modulator
|
T86836 | |
|
Formula |
Cl2H6N2Pt
|
| Canonical SMILES |
N.N.Cl[Pt]Cl
|
|
| InChI |
1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
|
|
| InChIKey |
LXZZYRPGZAFOLE-UHFFFAOYSA-L
|
|
| CAS Number | CAS 15663-27-1 | |
| TTD ID | D0U5HU | |
| DrugBank ID | DB00515 | |
| PubChem Compound ID | 5702198 | |
| PubChem Substance ID | ||
| ChEBI ID | NA | |
| ADReCS Drug ID | BADD_D00474 |
| ID | Name | Dose | Type | Drug Brand Name | Drug Dose | Drug Dosage Form | Experimental Species | Individuals Number | Test Sample | Ingredient | Effect | Relationship Classification | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | Name | Dose | Type | Drug Brand Name | Drug Dose | Drug Dosage Form | Experimental Species | Individuals Number | Test Sample | Ingredient | Effect | Relationship classification |